Medical technology company GE HealthCare (NASDAQ: GEHC) announced on Wednesday that it has introduced a new AI-enabled application orchestration feature, integrated into its True PACS and Centricity PACS systems, through a collaboration with Blackford.
This new offering aims to assist radiologists in managing increased workloads and exam complexities, enabling quicker diagnoses and treatments. The platform provides access to a catalog of third-party AI applications, covering areas from mammography to lung scans.
As clinician burnout rises - 49% of radiologists cited excessive bureaucratic tasks as a key issue in an RSNA survey - GE HealthCare's AI solutions focus on improving workflow efficiency. This aligns with the company's precision care framework, which integrates smart devices, targeted therapies, and digital solutions to enhance care quality.
GE HealthCare currently leads the U.S. Food and Drug Administration's (FDA) list of AI-enabled medical devices, with 80 clearances to date. The AI orchestration feature simplifies the integration of AI into clinical workflows, offering a streamlined process for healthcare providers to access and implement imaging AI solutions.
The new technology will be showcased at the Radiological Society of North America's annual meeting in Chicago from 1-4 December 2023.
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer